CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the Department of Defense Appropriations Act of 2007, passed by Congress last week, includes $1.1 million of funding dedicated to Alnylam’s ongoing development of RNAi therapeutics. Congressional support for this effort builds upon existing public sector-private sector partnerships that the company has formed to develop RNAi therapeutics for public health. This appropriation, combined with earlier funding from the government, supports the goal of Alnylam Biodefense to build a robust platform for developing RNAi therapeutics to combat natural or man-made biological threats that pose a potential risk to public health and national security.
